4 views left Get unlimited views with a free account

Subscribe to GlobalData Explorer

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Alagille Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 4 ongoing clinical trials involving Alagille Syndrome
Of the 4 trials,3 trials are in Phase II
Furthermore, 1 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Alagille Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Alagille Syndrome, a genetic disorder. North America and Europe are among some of the prominent regions involved in Alagille Syndrome-related drug trials.

Alagille Syndrome related clinical trials sponsors

Mirum Pharmaceuticals Inc, and Albireo Pharma Inc are a few notable sponsors for clinical trials involving Alagille Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drug involving Alagille Syndrome

Maralixibat chloride (Livmarli) is a key marketed drug involving Alagille Syndrome.

Maralixibat chloride (Livmarli) is an anti-pruritus agent. It functions via Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Inhibitor mechanism of action.  It is formulated as solution for oral route of administration. Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older. Livmarli received first approval in 2021 and is marketed in the US by Mirum Pharmaceuticals Inc.

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Visit Report Store